Phase III Study Shows Roche's Alecensa Improves PFS over Crizotinib in ALK-Positive NSCLC - Genetic Engineering & Biotechnology News

pharmaphorum

Phase III Study Shows Roche's Alecensa Improves PFS over Crizotinib in ALK-Positive NSCLC Genetic Engineering & Biotechnology News Roche said a second Phase III study has shown that non-small-cell lung cancer (NSCLC) patients treated with its oral anaplastic lymphoma kinase (ALK) inhibitor Alecensa® (alectinib) stayed alive without their disease worsening for significantly longer ... Alectinib Beats Crizotinib in Frontline ALK+ NSCLC ALEX TrialOncLive Roche's Alecensa notches trial win against Pfizer's XalkoriReuters all 20 news articles »

from Health - Google News http://ift.tt/2oks3h7